1
|
Cecchi M, Ninot G, Rebillard X, Thuret R, Droupy S, Ayuso D, Poinas G. [Which non pharmacological interventions should be offered to patients treated with androgen deprivation therapy for prostate cancer? A systematic review]. Prog Urol 2023; 33:287-306. [PMID: 37121810 DOI: 10.1016/j.purol.2023.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Revised: 02/24/2023] [Accepted: 03/27/2023] [Indexed: 05/02/2023]
Abstract
AIM Prostate cancer is a frequent disease and one of the main treatments used is androgen deprivation therapy, which is a therapy with disabling side effects. Non-pharmacological interventions (NPIs) are evidenced based, non-invasive interventions on human health. They are classified into five categories (physical, psychological, nutritional, digital, elemental). The NPIs sphere is booming and still remains underused in this context. METHODS A systematic review concerning randomized controlled trials was executed according to the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). We used the "Medline" and "Kalya Research" databases. After searching and selecting eligible publications, we included 37 randomized controlled trials. RESULTS The majority of articles concerned physical NPIs with 30 clinical studies, 3 publications dealt with nutritional NPIs, 2 with psychological NPIs and 2 articles concerned elemental NPIs. No publication about digital NPI was found. All of the studies aimed to manage and improve the side effects of treatment. No elemental NPI has demonstrated benefit. Only one psychological NPI and one nutritional NPI were effective. Five types of physical NPI protocols have shown efficacy. The main benefits related to physical abilities, body composition, osteoporosis, quality of life, fatigue, reduced cardiovascular risk and finally anxiety and depression. CONCLUSION Non-pharmacological interventions, especially physical ones, are effective in managing and reducing the side effects associated with androgen deprivation therapy and should be offered to patients in this context.
Collapse
Affiliation(s)
- M Cecchi
- Urologie, clinique Beau Soleil, 149, rue de la Taillade, 34070 Montpellier, France.
| | - G Ninot
- Institut Desbrest d'épidémiologie et de santé publique (Université de Montpellier-Inserm), 641, avenue du Doyen Gaston-Giraud, 34093 Montpellier, France
| | - X Rebillard
- Urologie, clinique Beau Soleil, 149, rue de la Taillade, 34070 Montpellier, France
| | - R Thuret
- Urologie et transplantation rénale, CHU Lapeyronie, 371, avenue du Doyen Gaston-Giraud, 34090 Montpellier, France
| | - S Droupy
- Urologie andrologie, CHU de Nîmes, 4, rue du Professeur Robert-Debré, 30900 Nîmes, France
| | - D Ayuso
- Urologie, centre hospitalier du Bassin de Thau, 11, boulevard Camille-Blanc, 34200 Sète, France
| | - G Poinas
- Urologie, clinique Beau Soleil, 149, rue de la Taillade, 34070 Montpellier, France
| |
Collapse
|
2
|
Rozet F, Mongiat-Artus P, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mathieu R, Ploussard G, Renard-Penna R, Brenot-Rossi I, Bruyere F, Cochet A, Crehange G, Cussenot O, Lebret T, Rebillard X, Soulié M, Brureau L, Méjean A. Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251]. Prog Urol 2021; 31:381-382. [PMID: 33941457 DOI: 10.1016/j.purol.2021.04.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- F Rozet
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France; Institut mutualiste Montsouris, 42, boulevard Jourdan, 75014 Paris, France.
| | - P Mongiat-Artus
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - C Hennequin
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - J B Beauval
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - P Beuzeboc
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - L Cormier
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - G Fromont-Hankard
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - R Mathieu
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - G Ploussard
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - R Renard-Penna
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - I Brenot-Rossi
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - F Bruyere
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - A Cochet
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - G Crehange
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - O Cussenot
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - T Lebret
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - X Rebillard
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - M Soulié
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - L Brureau
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| | - A Méjean
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, Maison de l'urologie, 11, rue Viète, 75017 Paris, France
| |
Collapse
|
3
|
Zarka M, Tretarre B, Rebillard X, Murez T, Daures JP, Azria D, Serre I, Brel D, Ramay AS, Reis Borges R, Gevorgyan A, Hutin M, Marchal S, Korahanis N, Iborra F, Thuret R. [Cancers of the external genital organs of male in Hérault: Results from the Hérault tumor register (RTH) over a period of 30 years (1987-2016)]. Prog Urol 2021; 31:282-292. [PMID: 33593695 DOI: 10.1016/j.purol.2020.08.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 07/25/2020] [Accepted: 08/13/2020] [Indexed: 10/22/2022]
Abstract
AIM The objective of this study is to present the history of cancers of the external genital organs of male in Hérault using data from the Hérault tumor register (RTH) over a period of 30 years. PATIENTS AND METHODS Using the RTH database, we studied the development of testicular germ cell tumors (TGCT) and penile cancer (PC) over 30 years, from 1987 to 2016. We analyzed the incidence and mortality data for these tumors. We compared these results to French, European and global data. RESULTS In 30 years of registration we have recorded 725 cases of TGCT and 175 cases of PC. The age standardized incidence rate (ASR) of TGCT has doubled between 1987 and 2016 (4.2 per 100,000 in 1987 and 9.3 per 100,000 in 2016). It was multiplied by 2.63 in the population of patients aged 30 to 44. There is a decrease of the mortality rate with a ASR of 0.8 deaths per 100,000 in 1987, and 0.4/100 000 in 2016. The PC incidence ASR was stable between 1987 and 2016 (0.4-0.9/100,000). Mortality is stable with a ASR between 0.1 and 0.3 deaths per 100,000 between 1987 and 2016. CONCLUSION The incidence of TGCT has increased sharply in the Hérault over the past 30 years, while a decrease in mortality has been observed. The proportion of seminomas is increasing; it has gone from 53 % to 60 % in 30 years in the Hérault. The incidence and mortality of PC shows a stability in the Hérault over the past 30 years.
Collapse
Affiliation(s)
- M Zarka
- Service d'urologie et transplantation rénale, CHU Montpellier Lapeyronie, 371, avenue du Doyen Gaston-Giraud, 34090 Montpellier, France.
| | - B Tretarre
- Registre des tumeurs de l'Hérault, Montpellier, France
| | - X Rebillard
- Service d'urologie, clinique beau soleil, Montpellier, France
| | - T Murez
- Service d'urologie et transplantation rénale, CHU Montpellier, Montpellier, France
| | - J P Daures
- Clinique beau soleil, IURC, Montpellier, France
| | - D Azria
- ICM, Univ Montpellier, inserm U 1194, Montpellier, France
| | - I Serre
- Service d'anatomopathologie, CHU Montpellier, Montpellier, France
| | - D Brel
- Service d'anatomopathologie, CH Béziers, Béziers, France
| | - A S Ramay
- Laboratoire de biologie médicale Medipath, Montpellier, France
| | - R Reis Borges
- Laboratoire de biologie médicale Labosud-Ob Biologie, Montpellier, France
| | - A Gevorgyan
- Polyclinique Saint-Privat, Boujan sur Libron, France
| | - M Hutin
- Service d'urologie, clinique beau soleil, Montpellier, France
| | - S Marchal
- Clinique du parc, Castelnau-le-lez, France
| | | | - F Iborra
- Service d'urologie et transplantation rénale, CHU Montpellier, Montpellier, France
| | - R Thuret
- Service d'urologie et transplantation rénale, CHU Montpellier, Montpellier, France
| | | |
Collapse
|
4
|
Peigné C, Trabelssi M, Poinas G, Segui B, Reis Borges R, Lamy P, Lacombe S, Livrozet M, Rebillard X. Performances diagnostiques du test urinaire Xpert®Bladder Cancer Monitor dans la surveillance de patients atteints de tumeurs de vessie n’infiltrant pas le muscle : résultats intermédiaires d’une étude prospective. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Trouche-Sabatier SG, Rebillard X, Iborra F, Azria D, Daures JP, Poinas G, Abdo N, Delbos O, Gevorgyan A, Marchal S, Guillon R, Millet I, Lamy PJ, Lauche O, Reis-Borges R, Serre I, Topart D, Tretarre B. [RHESOU (Registry in HErault Specialized in Onco-Urology) : the first French Registry specialized in Onco-Urology. One-year experience]. Prog Urol 2020; 30:1038-1044. [PMID: 33012630 DOI: 10.1016/j.purol.2020.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 08/13/2020] [Accepted: 09/06/2020] [Indexed: 10/23/2022]
Abstract
PURPOSE In 2016, the Herault tumor registry collected 1961cancers in urology (21.4 % from all Herault cancers this year). RHESOU was created to complete RTH' data with specific parameters in onco-urology. The aim of this study is to describe RHESOU and to give some examples with our first results. MATERIAL AND METHODS In November 2018, RHESOU (Registry HErault Specialised in Onco-Urology) was founded with the same registry recommendations. It collects specific oncologic parameters and also complete RTH's data. For each urological cancer, a specific survey with different choices was performed to collect a maximum of data which could be present in patients' file. These surveys were used for urological cancers cases that live in Herault in 2017. RESULTS In 2017, we collected 970 prostate cancers, 581 bladder cancers, 212 kidney cancers, 51 upper excretory tract cancers, 28 testicle cancers and 9 penil cancers. Our urological data collection gives many possibilities to create many requests for detailed analysis in urological cancers. In this article, we reported data from kidney, bladder and prostate cancers. CONCLUSIONS RHESOU is a new tool opened to the different urologic corporations (urologists, pathologists, oncologists, radiotherapists, radiologists) that permits an overview in urological cancers in Herault. Finally, one important aim is that this tool will be adapted when new treatments or new important parameters appear in the years ahead. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
| | - X Rebillard
- Comité de pilotage, Montpellier, France; Clinique Beau Soleil, Montpellier, France
| | - F Iborra
- Comité de pilotage, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - D Azria
- Comité de pilotage, Montpellier, France; Inserm U 1194, ICM, université Montpellier, Montpellier, France
| | - J-P Daures
- Comité de pilotage, Montpellier, France; Clinique Beau Soleil, Montpellier, France; IURC, Montpellier, France
| | - G Poinas
- Comité scientifique du RHESOU, Montpellier, France; Clinique Beau Soleil, Montpellier, France
| | - N Abdo
- Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - O Delbos
- Comité scientifique du RHESOU, Montpellier, France; Urodoc, Montpellier, France
| | - A Gevorgyan
- Comité scientifique du RHESOU, Montpellier, France; Polyclinique Saint-Privat Boujan sur Libron, Béziers, France
| | - S Marchal
- Comité scientifique du RHESOU, Montpellier, France; Urodoc, Montpellier, France
| | - R Guillon
- Comité scientifique du RHESOU, Montpellier, France; Clinique Beau Soleil, Montpellier, France
| | - I Millet
- Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - P-J Lamy
- Comité scientifique du RHESOU, Montpellier, France; Imagenome-inovie, Montpellier, France
| | - O Lauche
- Comité scientifique du RHESOU, Montpellier, France; Clinique Clémentville, Montpellier, France
| | - R Reis-Borges
- Comité scientifique du RHESOU, Montpellier, France; Inopath Labosud, Montpellier, France
| | - I Serre
- Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - D Topart
- Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - B Tretarre
- Comité de pilotage, Montpellier, France; Registre des tumeurs de l'Hérault, Montpellier, France
| | | |
Collapse
|
6
|
Gas J, Dominique I, Mathieu R, Poinas G, Cuvelier G, Rebillard X, Corbel L. [Radical prostatectomy for prostate cancer, perioperative management by French urologists in 2018]. Prog Urol 2020; 30:541-546. [PMID: 32646841 DOI: 10.1016/j.purol.2020.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 06/17/2020] [Accepted: 06/22/2020] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Prostatectomy (PT) is a common procedure performed by many urologists. In 2018, 20,207 prostatectomies were performed in France, and few studies evaluated the perioperative habits of urologists. As part of writing guidelines for enhanced recovery after surgery (ERAS) we wished to evaluate practice of urologists in their hospital management of a prostatectomy. MATERIEL AND METHODS A questionnaire was sent by Survey Monkey in June and July 2018 to all urologists who are members of the French Association of Urology. RESULTS One hundred and sixty seven urologists (14%) answered the questionnaire, 62% have private practice. The average number of operators per center performing PT was 4, with a median number of 70 interventions (0 to 486) per center in 2018. Open surgery is still gold standard (39.13%), followed by the robot-assisted transperitoneal laparoscopic (34.78%) and standard laparoscopic (24.22%). Alimentation, like first stand-up, was re-established on the first post-operative day, and the average hospital stay was 4±2 nights. The removal of the bladder catheter was most often performed at home by nurse (49.06%), one week after surgery. Only 10.06% of urologists systematically perform a cystography before removal urinary catheter. CONCLUSION The perioperative management of prostatectomy in France is relatively homogeneous, between urologists. The length of hospital stay remains important and could be reduced by proposing an ERAS protocol as has been obtained for cystectomy. LEVEL OF EVIDENCE III.
Collapse
Affiliation(s)
- J Gas
- Département d'urologie, andrologie et transplantation rénale, CHU de Toulouse, Toulouse, France
| | - I Dominique
- Service d'urologie, groupe hospitalier Diaconesses croix saint-Simon, Paris, France
| | - R Mathieu
- Service d'urologie, CHU de Rennes, Rennes, France
| | - G Poinas
- Service d'urologie, clinique Beausoleil, Montpellier, France
| | - G Cuvelier
- Service d'urologie, centre hospitalier de Cornouaille, Quimper, France
| | - X Rebillard
- Service d'urologie, clinique Beausoleil, Montpellier, France
| | - L Corbel
- Service d'urologie, hôpital privé des côtes d'Armor, Plerin, France
| | | |
Collapse
|
7
|
Thurin N, Rouyer M, Jové J, Gross-Goupil M, Haaser T, Rebillard X, Soulié M, De Pouvourville G, Capone C, Pierres M, Lamarque S, Bignon E, Droz-Perroteau C, Moore N, Blin P. Changes in therapeutic strategy in metastatic castration resistant prostate cancer (mCRPC) between 2012 and 2014 from the French nationwide claims database (SNDS). EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33183-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
8
|
Vlaeminck V, Rebillard X, Lamy P, Potiron E, Colin P, Irani J, Roumiguié M, Vincendeau S, Cussenot O, Colombel M, De La Taille A, Delagarde V, Lepers S, Guechot J, Armand-Labit V, Bendavid C, Dupuis M, Subtil F, Huot L, Ruffion A. Clinical value of the integration of Prostate Health Index (PHI) in multiparametric MRI-based diagnostic strategies to detect clinically-significant prostate cancer. Results from the French prospective multicenter PHI-1 study. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32914-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Méjean A, Rouprêt M, Rozet F, Bensalah K, Murez T, Game X, Rebillard X, Mallet R, Faix A, Mongiat-Artus P, Fournier G, Neuzillet Y. [Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19]. Prog Urol 2020; 30:221-231. [PMID: 32224294 PMCID: PMC7146722 DOI: 10.1016/j.purol.2020.03.009] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 03/25/2020] [Accepted: 03/25/2020] [Indexed: 12/16/2022]
Abstract
Objectif La population française est confrontée à la pandémie de COVID-19 et le système de santé a été réorienté en urgence pour la prise en charge des patients atteints du coronavirus. La prise en charge des cancers de l’appareil urinaire et génital masculin doit être adaptée à ce contexte. Matériel et méthode Un avis d’experts documenté par une revue de la littérature a été formulé par le Comité de Cancérologie de l’Association Française d’Urologie (CCAFU). Résultats La prise en charge médicale et chirurgicale des patients atteints de cancers de l’appareil urinaire et génital masculin doit être adaptée en modifiant les modalités de consultation, en priorisant les interventions en fonction du pronostic intrinsèque des cancers en tenant compte des comorbidités du patient. La protection des urologues vis-à-vis du COVID-19 doit être prise en considération. Conclusion Le CCAFU émet un avis d’experts quant aux mesures à prendre pour adapter la prise en charge des cancers de l’appareil urinaire et génital masculin au contexte de pandémie par COVID-19.
Collapse
Affiliation(s)
- A Méjean
- Comité de cancérologie de l'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - M Rouprêt
- Comité de cancérologie de l'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - F Rozet
- Comité de cancérologie de l'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - K Bensalah
- Comité de cancérologie de l'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - T Murez
- Comité de cancérologie de l'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - X Game
- Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - X Rebillard
- Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - R Mallet
- Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - A Faix
- Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - P Mongiat-Artus
- Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - G Fournier
- Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France
| | - Y Neuzillet
- Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France.
| | | |
Collapse
|
10
|
Villers A, Bessaoud F, Trétarre B, Grosclaude P, Malavaud B, Rebillard X, Iborra F, Daubisse L, Malavaud S, Roobol M, Heijnsdijk EA, de Koning HJ, Hugosson J, Rischmann P, Soulié M. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC). Prog Urol 2020; 30:252-260. [PMID: 32197936 DOI: 10.1016/j.purol.2020.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 02/16/2020] [Accepted: 02/18/2020] [Indexed: 11/26/2022]
Abstract
INTRODUCTION European Randomized Study of Screening for Prostate Cancer (ERSPC) mortality results were reported for 7 European countries (excluding France) and showed a significant reduction in Prostate cancer (PCa) mortality. As those results have not been part of the global ERSPC results, it is of interest to report PCa mortality at a median follow-up of 9 years for French section of ERSPC. MATERIAL AND METHODS Two administrative departments were involved in the study. Only men after randomization in the screening group were invited by mail to be screened by PSA testing with two rounds at 4-6 year intervals. Biopsy was recommended if PSA>=3.0 ng/mL. No information other that the French Association of Urology recommandations on the use of PSA was offered to the control group (own decision of physicians and patients). Follow up was based on cancer registry database. Contamination defined as the receipt of PSA testing in control arm was measured. Poisson regression models were used to estimate the Rate Ratio (RR) of PCa mortality and incidence in the screening vs. control arm. RESULTS Starting from 2003, 80,696 men aged 55-69 years were included. The percentage of men in the screening arm with at least one PSA test (compliance) was 31%. Compared to the control arm, PCa incidence increased by 10% in the screening arm (RR=1.10; 95% CI=[1.04-1.16], P=0.001), but PCa mortality did not differ (0.222 and 0.215 deaths/1000 person-years; RR=1.03[0.75-1.42], P=0.9). DISCUSSION Limitations include low participation rate. PSA testing in the control arm was observed in 32% of men (contamination). CONCLUSIONS Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- A Villers
- Department of Urology, University Lille, CHU Lille, Lille, France.
| | - F Bessaoud
- Hérault cancer registry, ICM Montpellier, Montpellier, France
| | - B Trétarre
- Hérault cancer registry, ICM Montpellier, Montpellier, France
| | | | - B Malavaud
- Department of Urology, University Toulouse, CHU Toulouse, Toulouse, France
| | - X Rebillard
- Department of Urology, Clinique Beau Soleil, Montpellier, France
| | - F Iborra
- Department of Urology, University Montpellier, CHU Montpellier, Montpellier, France
| | - L Daubisse
- Hérault cancer registry, ICM Montpellier, Montpellier, France
| | - S Malavaud
- Department of Public Health, University Toulouse, CHU Toulouse, Toulouse, France
| | - M Roobol
- Department of Urology, Erasmus University Medical center, Rotterdam, The Netherlands
| | - E A Heijnsdijk
- Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - H J de Koning
- Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - J Hugosson
- Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Göteborg, Göteborg, Sweden
| | - P Rischmann
- Department of Urology, University Toulouse, CHU Toulouse, Toulouse, France
| | - M Soulié
- Department of Urology, University Toulouse, CHU Toulouse, Toulouse, France
| |
Collapse
|
11
|
Bajeot A, Rebillard X, Lebret T, Descotes J, Gamé X, Roumiguié M, Corbel L, Soulié M. Un nouveau mode d’étude de terrain : la RCP sentinelle (RCPs). Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Thurin N, Rouyer M, Gross-Goupil M, Rebillard X, Soulié M, Haaser T, De Pouvourville G, Pierrès M, Chevalier J, Lamarque S, Jové J, Bignon E, Droz-Perroteau C, Moore N, Blin P. Épidémiologie du cancer de la prostate résistant à la castration et métastatique : données françaises à partir du SNDS. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mongiat-Artus P, Ploussard G, Mathieu R, Brureau L, Ouzzane A, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Rebillard X, Lebret T, Soulié M, Penna RR, Méjean A. RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate French ccAFU guidelines – Update 2018–2020: Prostate cancer. Prog Urol 2018; 28:S79-S130. [PMID: 30392712 DOI: 10.1016/j.purol.2018.08.011] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 08/14/2018] [Indexed: 12/31/2022]
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).
Cet article est retiré de la publication à la demande des auteurs car ils ont apporté des modifications significatives sur des points scientifiques après la publication de la première version des recommandations.
Le nouvel article est disponible à cette adresse: DOI:10.1016/j.purol.2019.01.007.
C’est cette nouvelle version qui doit être utilisée pour citer l’article.
This article has been retracted at the request of the authors, as it is not based on the definitive version of the text because some scientific data has been corrected since the first issue was published.
The replacement has been published at the DOI:10.1016/j.purol.2019.01.007.
That newer version of the text should be used when citing the article.
Collapse
Affiliation(s)
- F Rozet
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, institut mutualiste Montsouris, université René-Descartes, 42, boulevard Jourdan, 75674, Paris, France.
| | - C Hennequin
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service de radiothérapie, Saint-Louis Hospital, AP-HP, 75010, Paris, France
| | - J-B Beauval
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, oncologie médicale, institut universitaire du cancer Toulouse-Oncopole, CHU Rangueil, 31100, Toulouse, France
| | - P Beuzeboc
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital Foch, 92150, Suresnes, France
| | - L Cormier
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, CHU François-Mitterrand, 21000, Dijon, France
| | - G Fromont-Hankard
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; CHU de Tours, 2, boulevard Tonnellé, 37000, Tours, France
| | - P Mongiat-Artus
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, Paris cedex 10, France
| | - G Ploussard
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, clinique La Croix du Sud-Saint-Jean Languedoc, institut universitaire du cancer, 31100, Toulouse, France
| | - R Mathieu
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital de Rennes, 2, rue Henri-le-Guilloux, 35033, Rennes cedex 9, France
| | - L Brureau
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Inserm, U1085, IRSET, 97145 Pointe-à-Pitre, Guadeloupe
| | - A Ouzzane
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59000, Lille, France
| | - D Azria
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Inserm U1194, ICM, université de Montpellier, 34298, Montpellier, France
| | - I Brenot-Rossi
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Institut Paoli-Calmettes, 232, boulevard de Sainte-Marguerite, 13009, Marseille, France
| | - G Cancel-Tassin
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; GRC no 5 ONCOTYPE-URO, institut universitaire de cancérologie, Sorbonne université, 75020, Paris, France
| | - O Cussenot
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital Tenon, AP-HP, Sorbonne université, 75020, Paris, France
| | - X Rebillard
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, clinique mutualiste Beau-Soleil, 119, avenue de Lodève, 34070, Montpellier, France
| | - T Lebret
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital Foch, 92150, Suresnes, France
| | - M Soulié
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Centre hospitalier universitaire Rangueil, 31059, Toulouse, France
| | - R Renard Penna
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; GRC no 5 ONCOTYPE-URO, institut universitaire de cancérologie, Sorbonne université, 75020, Paris, France; Service de radiologie, hôpital Tenon, AP-HP, 75020, Paris, France
| | - A Méjean
- Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital européen Georges-Pompidou, université Paris Descartes, Assistance publique des hôpitaux de Paris (AP-HP), 75015, Paris, France
| |
Collapse
|
14
|
Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mongiat-Artus P, Ploussard G, Mathieu R, Brureau L, Ouzzane A, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Rebillard X, Lebret T, Soulié M, Renard Penna R, Méjean A. Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate. Prog Urol 2018; 28 Suppl 1:R81-R132. [DOI: 10.1016/j.purol.2019.01.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 08/14/2018] [Indexed: 01/02/2023]
|
15
|
Lavalette C, Cénée S, Rebillard X, Lamy PJ, Trétarre B, Menegaux F. Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.05.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
16
|
Delmas M, Hennequin C, Boussac-Zarebska M, Lukacs B, Nicolau J, Tupin P, Rebillard X. Incidence of Severe Adverse Events After External Beam Radiation Therapy for Prostate Cancer: A Population-Based Study. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Salomon L, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Rozet F, Azria D, Coloby P, Molinié V, Ravery V, Rebillard X, Richaud P, Villers A, Soulié M. Recommandations en onco-urologie 2013 du CCAFU : Cancer de la prostate. Prog Urol 2013; 23 Suppl 2:S69-101. [DOI: 10.1016/s1166-7087(13)70048-4] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
18
|
Bessede T, Soulié M, Mottet N, Rebillard X, Peyromaure M, Ravery V, Salomon L. [Status and medicolegal implications in France pT0 stage of prostate cancer: a study by the CC-AFU]. Prog Urol 2012. [PMID: 23178099 DOI: 10.1016/j.purol.2012.07.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVE To assess the frequency, circumstances, and possible medico-legal consequences of the pT0 prostate cancer, defined by the absence of tumor in a radical prostatectomy specimen. METHODS Six centers retrospectively identified all cases of pT0 and selectionned those that occurred without prior hormone therapy or prostate resection. Preoperative data, histological report and clinical and biological outcome were analyzed. The lawsuits' registry in pathology were consulted at insurance companies. RESULTS Thirty cases of pT0 prostate cancer (0.4%) were reported on 7693 patients. The median age was 63years, PSA 7.4ng/mL. The number of positive preoperative biopsies ranged from one to four for a median tumor length of 1mm (0.3 to 18mm). The biopsy Gleason score was 3+3 for 23 patients, less than 5 for six others and included a contingent of grade 4 in two patients. With a median follow-up of 82months, no clinical or biochemical recurrence was observed. One patient complaint for pT0 prostate was found in the insurances registry. CONCLUSION The occurrence of a prostate pT0 called into question all the diagnostic procedures and surgical indication. To avoid a forensic procedure, urologists should inform patients of the possibility of this situation before radical prostatectomy.
Collapse
Affiliation(s)
- T Bessede
- Service d'urologie, université Paris Sud, CHU de Bicêtre, France.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Riou O, Culine S, Rebillard X, Thezenas S, Faix A, Segui B, Pouessel D, Azria D. Combined Chemoradiation Therapy With Gemcitabine and Cisplatinum for Organ Preservation in Muscle-invasive Bladder Cancer: Long-term Results of a Phase I Trial. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Azria D, Charissoux M, Rebillard X, Fenoglietto P, Moscardo CL, Cristol L, Hay M, Ailleres N, Dubois J. Updated Results of the Montpellier IMRT Prostate Cancer Cohort: Focus on Elderly Patients. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Fassier JB, Charbotel B, Fort E, Rebillard X, Moreau JL, Borgogno C, Devonec M, Paparel P, Ruffion A. [A survey from the French Urology Association about sick leave prescriptions by 145 surgeons]. Prog Urol 2011; 21:479-85. [PMID: 21693360 DOI: 10.1016/j.purol.2011.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2010] [Revised: 12/28/2010] [Accepted: 02/01/2011] [Indexed: 10/18/2022]
Abstract
OBJECTIVES To describe and evaluate prescriptions of sick leave by urology surgeons for different kinds of interventions. METHODS Between January and April 2006, a web-based survey was completed by urology surgeons on a voluntary basis. The analyzed data pertained to personal characteristics of the surgeons, mean duration of sick leave for 15 interventions and the type of job of the patient (strenuous or not). Analyses were performed with software SAS™ version 9.2. Descriptive analyses were performed and Kruskal-Wallis test was used to search for statistically significant differences between variables (p<0,05). RESULTS One hundred and forty-eight surgeons were involved and 145 answers could be analyzed. Mean age of the surgeons was 46,3±9,4years. Urology surgeons were in the public sector (n=73/140; 52%), in private practice (n=43/140; 31%) or both (n=24/140; 17%). Kruskal-Wallis test showed that all patients who had a job considered as strenuous had significantly longer sick leave prescriptions. Younger surgeons (under 40) used to prescribe shorter sick leaves than their older counterparts. CONCLUSION Sick leave prescriptions of the urology surgeons were globally homogeneous in this survey. Only a few interventions were the occasion of discordant prescriptions depending upon the age or practice (public/private) of the surgeons. Several hypotheses could be further explored as regard the source of variation in sick leave prescriptions. These results are usable for those stakeholders who are interested in continuous medical education and evaluation.
Collapse
Affiliation(s)
- J-B Fassier
- UMRESTTE, Unité mixte INRETS/UCBL/InVS, France
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Salomon L, Azria D, Bastide C, Beuzeboc P, Cormier L, Cornud F, Eiss D, Eschwège P, Gaschignard N, Hennequin C, Molinié V, Mongiat Artus P, Moreau JL, Péneau M, Peyromaure M, Ravery V, Rebillard X, Richaud P, Rischmann P, Rozet F, Staerman F, Villers A, Soulié M. Recommandations en Onco-Urologie 2010 : Cancer de la prostate. Prog Urol 2010; 20 Suppl 4:S217-51. [PMID: 21129644 DOI: 10.1016/s1166-7087(10)70042-7] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Rebillard X, Segui B, Faix A, Hamid SA, Murez T, Daniel R, Riolacci N, Erbault M, Desplanques A, Pierre D, Coloby P. 276 Improving the quality of prostate cancer diagnosis and treatment using shared clinical practice indicators (CPI) and a computerised clinical pathway. BMJ Qual Saf 2010. [DOI: 10.1136/qshc.2010.041616.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
Mongiat-Artus P, Peyromaure M, Richaud P, Droz JP, Rainfray M, Jeandel C, Rebillard X, Moreau JL, Davin JL, Salomon L, Soulié M. Recommandations pour la prise en charge du cancer de la prostate chez l’homme âgé : un travail du comité de cancérologie de l’association française d’urologie. Prog Urol 2009; 19:810-7. [DOI: 10.1016/j.purol.2009.02.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Revised: 01/19/2009] [Accepted: 02/04/2009] [Indexed: 11/16/2022]
|
25
|
Peyromaure M, Beuzeboc P, Salomon L, Richaud P, Coloby P, Malavaud B, Rebillard X, Rischmann P, Villers A, Soulie M. [The screening of prostate cancer in 2009: overview of the oncology committee of the French Urological Association]. Prog Urol 2009; 20:17-23. [PMID: 20123523 DOI: 10.1016/j.purol.2009.09.033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2009] [Accepted: 09/29/2009] [Indexed: 01/22/2023]
Abstract
OBJECTIVE To analyze the impact of screening on prostate cancer (PCa) mortality, and to discuss the main points of controversy regarding this screening. METHODS A bibliographic analysis was made using Medline services (keywords: prostate cancer, screening). Only the randomized studies regarding the impact of PCa screening on specific mortality were taken into account. RESULTS Two randomized studies, comparing one group of screened men with another group of nonscreened men, were published this year with conflicting results. The American study PLCO included 76,693 men. After a follow-up of 7 years, it did not report a significant difference in terms of specific mortality between both arms: 2/10,000 deaths in the control group versus 1.7/10,000 in the screened arm (RR=1.13; IC 95%: 0.75-1.7). The European study ERSPC included 182,160 men. After 9 years of follow-up, it showed a significant 20% reduction of specific mortality rate in the screened group (RR=0.80; IC 90%: 0.65-0.98; p=0.04). Methodologically, the European study seems to be superior to the American study, in which the control group was biased by a high percentage of preinclusion screening. CONCLUSIONS This is the first time that a large randomized study shows a benefit of PCa screening regarding specific mortality. However, this issue remains to be clarified, due to the lack of data regarding the risk of "overdiagnosis" and the economic impact of screening.
Collapse
Affiliation(s)
- M Peyromaure
- Service d'urologie, hôpital Cochin, Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Jegu J, Tretarre B, Velten M, Guizard AV, Danzon A, Buemi A, Colonna M, Kadi-Hanifi AM, Ganry O, Molinie F, Bara S, Rebillard X, Grosclaude P. [Prostate cancer management and factors associated with radical prostatectomy in France in 2001]. Prog Urol 2009; 20:56-64. [PMID: 20123529 DOI: 10.1016/j.purol.2009.09.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2009] [Revised: 09/04/2009] [Accepted: 09/09/2009] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Prostate cancer was the most common cancer in men in France in 2005, and the second cause of male death from cancer. In this study, we analyzed clinical characteristics of patients with prostate cancer diagnosed in France in 2001 with a focus on therapeutic management of localized prostate cancers. PATIENTS AND METHODS A total of 2181 cases of prostate cancer diagnosed in 2001 from 11 French counties covered by a cancer registry were analyzed. A descriptive study of the clinical characteristics of patients was performed. Parameters studied included age, county, TNM stage, PSA value, Gleason score, D'Amico prognostic group, Charlson's comorbidity index and initial treatment modalities. For localized cancers, multivariate logistic regression analysis identified factors associated with radical prostatectomy. RESULTS The proportion of localized prostate cancer (T1 or T2) was 86.6 %. The use of invasive curative treatment (radical prostatectomy and radiotherapy) was 58.4 % for localized cancers. Significant differences in therapeutic management were found between counties. Radical prostatectomy was associated with age at diagnosis, D'Amico prognostic group and the presence of comorbidities. CONCLUSIONS Most of prostate cancers diagnosed in France in 2001 were clinically localized and were treated by invasive therapy. The consequences of these practices remain to be determined given the limited evolution of many prostate cancers and the frequency of adverse events related to invasive treatments.
Collapse
Affiliation(s)
- J Jegu
- Registre des cancers du Tarn, Albi, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A. État des lieux et facteurs de participation à l’étude européenne ERSPC de dépistage randomisé du cancer de la prostate par dosage sérique de l’antigène prostatique spécifique : départements français du Tarn et de l’Hérault. Prog Urol 2009; 19:487-98. [DOI: 10.1016/j.purol.2009.03.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2009] [Revised: 03/02/2009] [Accepted: 03/10/2009] [Indexed: 10/20/2022]
|
28
|
Cornud F, Villers A, Mongiat-Artus P, Rebillard X, Soulie M. Imagerie par résonance magnétique et cancer de la prostate. Prog Urol 2008; 18:621-33. [DOI: 10.1016/j.purol.2008.06.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2008] [Revised: 05/24/2008] [Accepted: 06/23/2008] [Indexed: 10/21/2022]
|
29
|
Panabières C, Vendrell J, Pellé O, Rebillard X, Riethdorf S, Müller V, Fabbro M, Pantel K. Identification of biologically active cancer cells in blood and bone marrow of cancer patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1001 Background: Metastasis is the main cause of cancer-related death. Single disseminated tumor cells (DTC) can be detected by sensitive immunocytochemical and molecular technologies, but it is still unclear whether these cells are viable and biologically active. Methods: We applied a novel enzyme-linked immunospot assay (‘EPISPOT‘) that reveals a fingerprint of specific proteins secreted from single viable epithelial tumor cells. The membrane of ELISPOT plates were coated with monoclonal antibodies against the tumor-associated marker proteins mucin-1 (MUC1) for breast cancer and prostate-specific antigen (PSA) for prostate cancer. In addition, dual fluorescent EPISPOT assays were developed to characterize MUC1+ and PSA+ cells (i.e. CK19, FGF2 secretion). Results: Even in the absence of overt metastases (stage M0), the EPISPOT assay revealed viable tumor cells in the peripheral blood of 65% of prostate cancer patients (n=31) and the bone marrow of 54% of breast cancer patients (n=37). Respective samples from non-carcinoma controls were EPISPOT- negative, whereas 80 to 100% of samples from metastatic patients (stage M1, n=40) were positive. The number of EPISPOT-positive cells in M0-patients ranged from 2 to 197 in the blood of prostate cancer patients and 1 to 262 in the bone marrow of breast cancer patients, while M1- patients showed significantly higher counts (prostate cancer, 1–684; breast cancer, 4–813). Interestingly, subsets of MUC1- or PSA-secreting cells expressed a breast stem cell-like phenotype (MUC1-/CK19+) or secreted FGF-2 as factor relevant for the growth of DTC, respectively. Conclusions: A significant fraction of cancer patients harbor viable and biologically active tumor cells in their blood and bone marrow, even in the absence of overt metastases. The multiparameter EPISPOT assay helps to identify these putative metastatic precursor cells. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Panabières
- Lapeyronie Hospital, Virology Department, CHU Mont, Montpellier, France; Beau Soleil Clinic, Montpellier, France; Institute of Tumor Biology, UKE, Hamburg, Germany; Institute of Tumor Biology, Hamburg, Germany; Val d’Aurelle Clinic, Montpellier, France
| | - J. Vendrell
- Lapeyronie Hospital, Virology Department, CHU Mont, Montpellier, France; Beau Soleil Clinic, Montpellier, France; Institute of Tumor Biology, UKE, Hamburg, Germany; Institute of Tumor Biology, Hamburg, Germany; Val d’Aurelle Clinic, Montpellier, France
| | - O. Pellé
- Lapeyronie Hospital, Virology Department, CHU Mont, Montpellier, France; Beau Soleil Clinic, Montpellier, France; Institute of Tumor Biology, UKE, Hamburg, Germany; Institute of Tumor Biology, Hamburg, Germany; Val d’Aurelle Clinic, Montpellier, France
| | - X. Rebillard
- Lapeyronie Hospital, Virology Department, CHU Mont, Montpellier, France; Beau Soleil Clinic, Montpellier, France; Institute of Tumor Biology, UKE, Hamburg, Germany; Institute of Tumor Biology, Hamburg, Germany; Val d’Aurelle Clinic, Montpellier, France
| | - S. Riethdorf
- Lapeyronie Hospital, Virology Department, CHU Mont, Montpellier, France; Beau Soleil Clinic, Montpellier, France; Institute of Tumor Biology, UKE, Hamburg, Germany; Institute of Tumor Biology, Hamburg, Germany; Val d’Aurelle Clinic, Montpellier, France
| | - V. Müller
- Lapeyronie Hospital, Virology Department, CHU Mont, Montpellier, France; Beau Soleil Clinic, Montpellier, France; Institute of Tumor Biology, UKE, Hamburg, Germany; Institute of Tumor Biology, Hamburg, Germany; Val d’Aurelle Clinic, Montpellier, France
| | - M. Fabbro
- Lapeyronie Hospital, Virology Department, CHU Mont, Montpellier, France; Beau Soleil Clinic, Montpellier, France; Institute of Tumor Biology, UKE, Hamburg, Germany; Institute of Tumor Biology, Hamburg, Germany; Val d’Aurelle Clinic, Montpellier, France
| | - K. Pantel
- Lapeyronie Hospital, Virology Department, CHU Mont, Montpellier, France; Beau Soleil Clinic, Montpellier, France; Institute of Tumor Biology, UKE, Hamburg, Germany; Institute of Tumor Biology, Hamburg, Germany; Val d’Aurelle Clinic, Montpellier, France
| |
Collapse
|
30
|
Schröder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, Villers A, Rebillard X, Ciatto S, Zappa M, Berenguer A, Paez A, Hugosson J, Lodding P, Recker F, Kwiatkowski M, Kirkels WJ. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92 Suppl 2:1-13. [PMID: 14983946 DOI: 10.1111/j.1464-410x.2003.04389.x] [Citation(s) in RCA: 97] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- F H Schröder
- Department of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Affiliation(s)
- A Villers
- Department of Urology of Lille, Hôpital Huriez, France.
| | | | | | | | | |
Collapse
|
32
|
Lobaccaro JM, Boudon C, Lumbroso S, Lechevallier E, Mottet N, Rebillard X, Sultan C. [5 alpha-reductase and prostate]. Ann Endocrinol (Paris) 1998; 58:381-92. [PMID: 9685996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The human prostate is a complex organ composed of four glandular zones that differ in their histology and biology. In addition to this anatomical organization, the prostate is mainly composed of epithelial and mesenchymal tissues. Two pathologies affect the growth of the prostate: cancer and benign prostatic hyperplasia. Anatomical and pathological studies have shown that stromal enlargement is the first step in the process of BPH and that both transition and periurethral regions are the exclusive sites of origin. Because the first step of androgen action is the reduction of testosterone into dihydrotestosterone by the 5 alpha-reductase, it have been postulated that modification of this enzymatic activity may play an important role in BPH development. However DHT production alone cannot explain the hyperplastic development of the gland. Thus it has also been postulated that androgen-growth factor interaction may be an important feature of this growth: these growth factors include the IGF axis. An interaction between androgen pathway and sympathethic system, via alpha-adrenoreceptor may also be suspected.
Collapse
Affiliation(s)
- J M Lobaccaro
- INSERM U439, Pathologie moléculaire des récepteurs nucléaires, Montpellier, France
| | | | | | | | | | | | | |
Collapse
|
33
|
|
34
|
Salmon JM, Yassine M, Vo-Dinh T, Isola NR, Rebillard X, Viallet P. Discrimination between tumour and normal cells by staining with 3,4,5,6,16,17-hexadehydro-16-(methoxycarbonyl)-19 alpha-methyl-20 alpha-oxayohimbanium: the uracil ring as a target for the specific interaction between RNA(s) and the fluorescent probe. Anticancer Res 1996; 16:1881-6. [PMID: 8712716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
3,4,5,6,16,17-Hexadehydro-16-(methoxycarbonyl)-19 alpha-methyl-20 alpha-oxayohimbanium (Alstonine) is a fluorescent alcaloid which has been known to stain tumour cells more efficiently than normal ones. In this paper the spectral properties of Alstonine were first investigated and its capability for preferential staining of tumour cells verified in culture using SK-OV-3 cells as tumour cells and Mouse 3T3 fibroblasts as controls. Then interactions between Alstonine and biological macromolecules were investigated to provide the rationale for preferential labelling. Molecular filtration techniques have demonstrated that binding occurs only with RNA molecules. Similar experiments were performed with different isopolynucleotides to find an explanation for that specificity. They provide evidence that binding occurs only in the presence of a uridyl ring. This is consistent with the specificity of the linkage to RNA. As the linkage of Alstonine with RNA did not induce any shift or obvious change in the intensity of its fluorescence spectrum, it is concluded that the binding might involve the side chain of the fluorescent compound.
Collapse
Affiliation(s)
- J M Salmon
- Laboratory of Physical Chemistry, University of Perpignan, France
| | | | | | | | | | | |
Collapse
|
35
|
Lobaccaro JM, Boudon C, Lechevallier E, Mottet N, Rebillard X, Lumbroso S, Gibelin B, Sultan C. Effect of finasteride (Proscar) on the proliferation of cultured epithelial and stromal cells from normal and hyperplastic human prostates. Cell Mol Biol (Noisy-le-grand) 1996; 42:511-8. [PMID: 8828906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Finasteride is a potent 5 alpha-reductase inhibitor which has proven useful in the clinical management of benign prostatic hyperplasia. To determine a potential mode of action for finasteride in prostatic cell proliferation, we have studied the incorporation of [3H]-thymidine into the DNA of cultured epithelial and stromal cells from normal and hyperplastic human prostates. The effects of short treatment with 10(-9) M and 10(-6) M finasteride (48 hrs.) on the incorporation of labelled thymidine were studied. A significant effect of finasteride on prostatic cell proliferation was observed at 10(-6) M for both epithelium and stroma from normal prostate: the rate of thymidine incorporation decreased to 80 +/- 3% (p < 0.001) and 55 +/- 10% (p < 0.01), respectively, compared to the control cells. As observed for normal prostates, this rate of thymidine incorporation was less for hyperplastic epithelium (70 +/- 4%, p < 0.001) than that observed for the hyperplastic stroma (74 +/- 4%, p < 0.01). These data clearly demonstrate that the reduction of the prostate volume observed in BPH treatment by finasteride is partly due to an inhibition of cell proliferation. However, the absence of complete inhibition of cell proliferation at 10(-6) M, a concentration known to strongly inhibit the 5 alpha-reductase activity, supports the hypothesis that factors other than DHT are necessary to induce prostatic cell proliferation.
Collapse
Affiliation(s)
- J M Lobaccaro
- Institut National de la Santé et de la Recherche Médicale, INSERM Unité 439, Montpellier, France
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Poulat F, Girard F, Chevron MP, Gozé C, Rebillard X, Calas B, Lamb N, Berta P. Nuclear localization of the testis determining gene product SRY. J Biophys Biochem Cytol 1995; 128:737-48. [PMID: 7876301 PMCID: PMC2120386 DOI: 10.1083/jcb.128.5.737] [Citation(s) in RCA: 97] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
We have studied the expression of the human SRY protein (termed p27SRY) in two different cell lines by using specific antibodies. Confocal microscopy enabled us to localize p27SRY precisely in the nucleus in a discrete punctuate pattern. Furthermore, through microinjection experiments, we have demonstrated that the localization of the p27SRY protein into the nucleus was an event involving the NH2-terminal part of the high mobility group (HMG) domain. With the help of several synthetic peptides and various p27SRY mutants, we have characterized a bipartite basic motif in this part of the protein corresponding to a nuclear localization signal. This nuclear localization signal appears to be highly conserved in SRY box- and HMB box-containing proteins, suggesting common properties of nuclear targeting within the HMG box protein family.
Collapse
Affiliation(s)
- F Poulat
- Centre de Recherche de Biochimie Macromoléculaire, CNRS/INSERM, Montpellier, France
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Chambon M, Rebillard X, Rochefort H, Brouillet JP, Baldet P, Guiter J, Maudelonde T. Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumors. Prostate 1994; 24:320-5. [PMID: 7516070 DOI: 10.1002/pros.2990240608] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
We quantified cathepsin D by immunoradiometric assay (IRMA) and quantitative immunohistochemistry in fifteen human prostate cancers, seventeen BPH, and nine normal prostates. The cytosolic cathepsin D concentration was higher in prostatic carcinoma (mean: 31.5 pmol/mg cytosol proteins; range: 10.2-66.2) than in normal prostate (16.0 pmol/mg cytosol proteins; 7.2-25.5; P = 0.01). Prostatic hyperplasia showed intermediate values (20.2 pmol/mg cytosol proteins; 7.6-33.9). Immunostaining of cathepsin D and prostatic acid phosphatase on serial frozen sections of prostate tissues was only observed in glandular epithelial cells. Immunostaining was quantified by computer-assisted image analysis as an quantitative immuno-cytochemical score (QIC score) expressed in arbitrary units (A.U.). QIC scores for cathepsin D were dispersed and had a tendency to be higher in benign prostatic hyperplasia (mean: 178.3 A.U.; range: 95-297) compared to normal prostate (85.2 A.U.; 2-173 P < 0.01) and prostatic carcinoma (90.0 A.U.; 21-179 P = 0.0002). Prostatic cathepsin D levels in cytosols or immunostaining sections were independent of other clinicobiological parameters.
Collapse
Affiliation(s)
- M Chambon
- Laboratoire de Biologie Cellulaire and INSERM U148, Montpellier, France
| | | | | | | | | | | | | |
Collapse
|
38
|
Costa P, Soulie-Vassal ML, Sarrazin B, Rebillard X, Navratil H, Bali JP. Adrenergic receptors on smooth muscle cells isolated from human penile corpus cavernosum. J Urol 1993; 150:859-63. [PMID: 8393943 DOI: 10.1016/s0022-5347(17)35633-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The effect of the alpha-adrenergic blocker moxisylyte was examined on smooth muscle cells isolated from human corpus cavernosum, and compared with that of other adrenergic agents and papaverine. Isolated smooth muscle cells were shown to contract (reduction of the mean cell length) under noradrenaline and carbachol stimulations in a time-dependent and concentration-dependent manner (maximum at 30 seconds, EC50 [noradrenaline] = 5 nM., EC50 [carbachol] = 1 nM.). The contractile effect of noradrenaline was dose-dependently inhibited by moxisylyte (IC50 = 0.5 +/- 0.2 microM.) and by prazosin (IC50 = 0.9 +/- 0.2 microM.). The dose-response curves were parallel and no statistically significant difference could be shown between the IC50 values. The alpha 2-adrenergic antagonist tolazoline also inhibited noradrenaline-induced contraction, whereas the alpha-adrenergic agonist methoxamine did not change the mean cell length. As expected, isoproterenol caused relaxation of noradrenaline-precontracted cells by interaction with a beta 2-adrenergic receptor. Papaverine was also found to inhibit the contraction induced by noradrenaline in a dose-dependent manner (IC50 = 2 +/- 0.3 nM.). Tritiated-dihydroergocryptine (3H-DHE) specific binding was competitively inhibited by moxisylyte and prazosin with the same IC50 value of 0.01 microM. Methoxamine and tolazoline also inhibited this binding with lower affinity (IC50 = 0.1 +/- 0.02 microM.), while isoproterenol did not change specific binding. Scatchard plots from saturation experiments with 3H-DHE and with 3H-N-methyl scopolamine revealed the presence of 15 times more adrenergic than muscarinic binding sites (650,000 and 45,000 sites per cell, respectively). Together, these data support evidence for the presence of postsynaptic alpha 1-adrenergic receptors on smooth muscle cells from human corpus cavernosum. These receptors are coupled with the contraction of the cell and are blocked by the alpha 1-adrenergic antagonists moxisylyte or prazosin. They also show that the phosphodiesterase inhibitor papaverine and the beta-adrenergic agonist isoproterenol induced relaxation. This model constitutes a new approach to study the potential targets of the adrenergic agents in the erectile tissue.
Collapse
Affiliation(s)
- P Costa
- Service d'Urologie, C.H.U. Gaston Doumergue, Nimes and Faculté de Pharmacie, Montpellier, France
| | | | | | | | | | | |
Collapse
|
39
|
Cristol JP, Mourad G, Rebillard X, Guiter J, Mion C. [Coronary ischemia after kidney transplantation in patients over 60 years of age]. Presse Med 1991; 20:2019-21. [PMID: 1837116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Many elderly patients (aged over 60) are waiting for renal allograft but are considered a risk population for myocardial infarction or sudden cardiac death. Between 1987 and January 1st, 1990, 22 elderly patients (16 men and 6 women; mean age 63.4 +/- 0.7 years; range 60-69 years) underwent cadaveric kidney transplantation. Twenty patients had been on haemodialysis for 4.8 +/- 1 years (range: 1-16.3), one had been on peritoneal dialysis for 5 years and one had developed chronic rejection of a previous cadaveric allograft. Among these 22 patients, 6 (27 percent) developed antibodies directed against the random lymphocyte panel and one had a second transplant. Cardiovascular risk factors were systematically estimated, including medical history, cervical arterial Doppler, echocardiography and stress thallium testing (STT). Coronary angiography was performed if there was evidence of myocardial ischaemia. STT did not show any coronary disease in 16 patients and was not maximal (less than 60 percent of maximal theoretical stress) in 4 patients. In 2 patients, STT showed myocardial ischaemia: one, with a history of angina, underwent coronary angiography and angioplasty; the other had silent ischaemia and refused coronary angiography. Two patients died of myocardial infarction. One of them was the patient with silent ischaemia and positive STT test. The patient with angioplasty had a successful transplantation 20 months later, without any cardiovascular complication. After 9 to 32 months of follow-up, 19 patients have functioning allografts (mean serum creatinine level 151 +/- 6 mumol/l). One patient lost his kidney from urinary fistula. Eight patients (36 percent) developed acute rejection and all responded to intravenous corticosteroids. No immunological transplant loss was observed. After 18 months, the graft actuarial survival rate was 85 percent. We conclude that elderly patients free of clinical or silent myocardial ischaemia are good transplant recipients. The cardiovascular risk could be prevented by using STT during the pretransplant screening. If the STT is not maximal or shows coronary ischaemia, coronary angiography is mandatory.
Collapse
Affiliation(s)
- J P Cristol
- Service de Néphrologie, Hôpital Lapeyronie, Montpellier
| | | | | | | | | |
Collapse
|
40
|
Fabre JM, Rebillard X. [Etiologies of peritonitis]. Soins Chir 1989:14-8. [PMID: 2602734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
41
|
Domergue J, Rebillard X, Briandet H. [Surgical treatment of generalized peritonitis]. Soins Chir 1989:25-7. [PMID: 2602736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|